Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

307
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
307
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

359
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
359
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

203
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
203

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Steatotic liver disease in Latin America: current views and perspectives.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis-By Addressing One Issue Do We Create Another? Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Editorial: Pushing Forward With Pharmacotherapies for Patients With Alcohol-Associated Cirrhosis-Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Implementation of Mobile-Based Programs for Alcohol Cessation in the Treatment of Alcohol-associated Liver Disease: Protocol for a Type 1 Hybrid Implementation-Effectiveness Trial.

JMIR research protocols·2026
Same author

Serum HMGB1 and Alcohol-Related Liver Disease.

Journal of clinical medicine·2026
Same author

Letter: Unmasking the Risks-The Need for Robust Data on Baclofen in Cirrhotic Patients. Authors' Reply.

Alimentary pharmacology & therapeutics·2026

相关实验视频

Updated: Jan 13, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.4K

综合饮酒障碍和肝脏疾病管理综合管理

Hanna Blaney1, Adelina Horhat2, Abdulmalik Saleem3

  • 1Medstar Transplant Hepatology Institute, MedStar Georgetown University Hospital, Washington, District of Columbia.

Seminars in liver disease
|October 28, 2025
PubMed
概括

与酒精相关的肝病 (ALD) 和酒精使用障碍 (AUD) 的综合治疗改善了患者的治疗结果. 这种多学科的方法是可行的和有效的管理这些双重条件.

更多相关视频

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.5K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K

相关实验视频

Last Updated: Jan 13, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.4K
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.5K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 成 药物 药物 药物 药物
  • 公共卫生 公共卫生

背景情况:

  • 与酒精相关的肝病 (ALD) 是与危险的酒精消费相关的全球主要健康问题.
  • 酒精使用障碍 (AUD) 经常与ALD同时发生,使患者管理复杂化.
  • 目前在ALD患者中AUD的治疗率仍然很低,这突显了严重的护理差距.

研究的目的:

  • 审查AUD和ALD的流行病学,诊断和治疗.
  • 检查AUD和ALD同时发生的成功综合护理模型.
  • 识别知识缺口和管理这些条件的未来研究方向.

主要方法:

  • 关于AUD和ALD流行病学,诊断和治疗的文献综述.
  • 综合护理模型的分析,涉及肝病学家和AUD专家.
  • 讨论研究需求,包括移植前护理和减少伤害.

主要成果:

  • 综合护理模式在减少酒精复发,医疗保健利用和改善死亡率方面表现有前途.
  • 多学科护理对于解决AUD和ALD的双重病理是必不可少的.
  • 成功的综合护理证明了可行性和有效性.

结论:

  • 对AUD和ALD的综合护理是有效的和可行的.
  • 解决AUD对于全面的ALD管理至关重要.
  • 未来的研究应该专注于扩大综合护理,减少伤害和移植前支持.